** Shares of drug developer Rapt Therapeutics RAPT.O fall 42.4% to $1.66
** Co says based on recent feedback from the U.S. FDA it has stopped development of its drug Zelnecirnon, for eczema and asthma
** The decision follows a clinical hold placed on the drug's trial by the FDA in February after a serious case of liver injury in one of the patients
** Co says it will identify a new experimental therapy to develop in H1 2025
** Including session's move, stock down 93.4%
(Reporting by Puyaan Singh and Christy Santhosh)
((Puyaan.Singh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。